All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
CANDOR study: should Dara-Kd become the new SOC for len refractory patients with RRMM?
Bookmark this article
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, María Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answers the question: Should daratumumab, carfilzomib, lenalidomide and dexamethasone combination become the new standard of care for lenalidomide refractory patients with relapsed/refractory multiple myeloma based on the CANDOR trial results?
María Victoria Mateos discusses the results of the late-breaking, phase III, randomized CANDOR trial, that was conducted in relapsed or refractory patients with myeloma. She explains the efficacy of the drug regimens in the patient population.
CANDOR study: should Dara-Kd become the new SOC for len refractory patients with RRMM?
Your opinion matters
57 votes - 5 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox